Home > Insider Trading > Filing (0001455244-11-000030)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
827809	Qlt Inc	QLTI	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1360509	Florian Schonharting	Ostergade 24A, 1 Dk-1100 Copenhagen K G7	No	No	Yes	No
1451330	K/S Equity Public Nb	Ostergade 24A, 1 Dk-1100 Copenhagen K G7	No	No	Yes	No
1451331	Cora Madsen	Ostergade 24A, 1 Dk 1100 Copenhagen K G7	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares, No Par Value	Disposition	2011-08-30	128,287	$7.26	7,399,326	No	4	S	Direct
Common Shares, No Par Value	Disposition	2011-08-31	1,700	$7.24	7,397,626	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.10 to $7.39 inclusive. The Reporting Owners undertake to provide to QLT, Inc., any security holder of QLT, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.22 to $7.25 inclusive.
Reported shares are owned directly by NB Public Equity K/S (the "Fund"), and indirectly by the other listed Reporting Owners.
Florian Schonharting is a direct investor in a limited partner in the Fund and a director of Nordic Biotech Advisors ApS, which owns 100% of the shares of NB Public Equity Komplementar ApS, the general partner of the Fund. Cora Madsen is a director of NB Public Equity Komplementar ApS, the general partner of the Fund. Mr. Schonharting and Ms. Madsen disclaim beneficial ownership in the securities, except to the extent of their pecuniary interest therein.